Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 15 May 2019
Padeliporfin for untreated localised prostate cancer (TA546)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 21 November 2018
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 28 September 2016
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 August 2016Published date: 25 May 2016
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 24 August 2016
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 July 2016Published date: 27 June 2012
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 July 2016Published date: 27 April 2016
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 27 January 2016
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 23 July 2014
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 28 June 2006
Enzalutamide with androgen deprivation therapy for untreated metastatic hormone-sensitive prostate cancer [ID1605]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 22 May 2020
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate cancer (hormone refractory) - atrasentan [ID390]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate cancer (prevention) - dutasteride [ID75]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Enzalutamide for the treatment of hormone refractory prostate cancer TA316Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer (ID1174)Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide for treating metastatic hormone-sensitive prostate cancer ID1534Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Darolutamide for treating non-metastatic hormone-relapsed prostate cancer ID1443Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC